A novel non-canonical Wnt signature for prostate cancer aggressiveness

Activation of the Canonical Wnt pathway (CWP) has been linked to advanced and metastatic prostate cancer, whereas the Wnt5a-induced non-canonical Wnt pathway (NCWP) has been associated with both good and poor prognosis. A newly discovered NCWP, Wnt5/Fzd2, has been shown to induce epithelial-to-mesenchymal transition (EMT) in cancers, but has not been investigated in prostate cancer. The aim of this study was to investigate if the CWP and NCWP, in combination with EMT, are associated with metabolic alterations, aggressive disease and biochemical recurrence in prostate cancer. An initial analysis was performed using integrated transcriptomics, ex vivo and in vivo metabolomics, and histopathology of prostatectomy samples (n=129), combined with at least five-year follow-up. This analysis detected increased activation of NCWP through Wnt5a/ Fzd2 as the most common mode of Wnt activation in prostate cancer. This activation was associated with increased expression of EMT markers and higher Gleason score. The transcriptional association between NCWP and EMT was confirmed in five other publicly available patient cohorts (1519 samples in total). A novel gene expression signature of concordant activation of NCWP and EMT (NCWP-EMT) was developed, and this signature was significantly associated with metastasis and shown to be a significant predictor of biochemical recurrence. The NCWP-EMT signature was also associated with decreased concentrations of the metabolites citrate and spermine, which have previously been linked to aggressive prostate cancer. Our results demonstrate the importance of NCWP and EMT in prostate cancer aggressiveness, suggest a novel gene signature for improved risk stratification, and give new molecular insight.

[1]  T. Bathen,et al.  A PET/MRI study towards finding the optimal [18F]Fluciclovine PET protocol for detection and characterisation of primary prostate cancer , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  T. Bathen,et al.  A Balanced Tissue Composition Reveals New Metabolic and Gene Expression Markers in Prostate Cancer , 2016, PloS one.

[3]  Wenliang Li,et al.  Epithelial-mesenchymal transition in human cancer: comprehensive reprogramming of metabolism, epigenetics, and differentiation. , 2015, Pharmacology & therapeutics.

[4]  T. Rachner,et al.  WNT5A Has Anti‐Prostate Cancer Effects In Vitro and Reduces Tumor Growth in the Skeleton In Vivo , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  V. Adhami,et al.  Role of epithelial mesenchymal transition in prostate tumorigenesis. , 2015, Current pharmaceutical design.

[6]  Leonid Peshkin,et al.  A Noncanonical Frizzled2 Pathway Regulates Epithelial-Mesenchymal Transition and Metastasis , 2014, Cell.

[7]  V. Sherwood,et al.  WNT Signaling: an Emerging Mediator of Cancer Cell Metabolism? , 2014, Molecular and Cellular Biology.

[8]  T. Bathen,et al.  Gene signatures ESC, MYC and ERG-fusion are early markers of a potentially dangerous subtype of prostate cancer , 2014, BMC Medical Genomics.

[9]  L. Qin,et al.  Challenging role of Wnt5a and its signaling pathway in cancer metastasis (Review) , 2014, Experimental and therapeutic medicine.

[10]  K. Moon,et al.  Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction , 2014, British Journal of Cancer.

[11]  F. Pontén,et al.  WNT5A-mediated β-catenin-independent signalling is a novel regulator of cancer cell metabolism , 2013, Carcinogenesis.

[12]  Lei Wang,et al.  Regulation of prostate cancer cell migration toward bone marrow stromal cell-conditioned medium by Wnt5a signaling. , 2013, Molecular medicine reports.

[13]  Anirban P. Mitra,et al.  Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy , 2013, PloS one.

[14]  Arend Heerschap,et al.  Spatially matched in vivo and ex vivo MR metabolic profiles of prostate cancer – investigation of a correlation with Gleason score , 2013, NMR in biomedicine.

[15]  T. Bathen,et al.  Spermine and Citrate as Metabolic Biomarkers for Assessing Prostate Cancer Aggressiveness , 2013, PloS one.

[16]  R. Moon,et al.  WNT signalling pathways as therapeutic targets in cancer , 2012, Nature Reviews Cancer.

[17]  J. Waxman,et al.  Wnt/β-catenin signalling in prostate cancer , 2012, Nature Reviews Urology.

[18]  L. Egevad,et al.  Emphasizing the role of Wnt5a protein expression to predict favorable outcome after radical prostatectomy in patients with low-grade prostate cancer , 2012, Cancer medicine.

[19]  J. Halgunset,et al.  Changes in Gene Transcription Underlying the Aberrant Citrate and Choline Metabolism in Human Prostate Cancer Samples , 2012, Clinical Cancer Research.

[20]  Paul Polakis,et al.  Wnt signaling in cancer. , 2012, Cold Spring Harbor perspectives in biology.

[21]  R. Dahiya,et al.  Wnt signaling pathways in urological cancers: past decades and still growing , 2012, Molecular Cancer.

[22]  E. Vazquez,et al.  Activation of β-Catenin Signaling in Androgen Receptor–Negative Prostate Cancer Cells , 2011, Clinical Cancer Research.

[23]  Hideaki Mizuno,et al.  Molecular classification of prostate cancer using curated expression signatures , 2011, Proceedings of the National Academy of Sciences.

[24]  T. Andersson,et al.  Elevated Level of Wnt5a Protein in Localized Prostate Cancer Tissue Is Associated with Better Outcome , 2011, PloS one.

[25]  J. Halgunset,et al.  A new method to provide a fresh frozen prostate slice suitable for gene expression study and MR spectroscopy , 2011, The Prostate.

[26]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[27]  Zhenyu Jia,et al.  In silico estimates of tissue components in surgical samples based on expression profiling data. , 2010, Cancer research.

[28]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[29]  A. Evans,et al.  Prostate tissue composition and MR measurements: investigating the relationships between ADC, T2, K(trans), v(e), and corresponding histologic features. , 2010, Radiology.

[30]  N. Oue,et al.  Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase , 2010, Oncogene.

[31]  A. Vidal-Puig,et al.  Wnt signalling and the control of cellular metabolism. , 2010, The Biochemical journal.

[32]  M. Gerstein,et al.  Molecular sampling of prostate cancer: a dilemma for predicting disease progression , 2010, BMC Medical Genomics.

[33]  W. Birchmeier,et al.  Interplay of cadherin-mediated cell adhesion and canonical Wnt signaling. , 2010, Cold Spring Harbor perspectives in biology.

[34]  A. Silver,et al.  The opposing roles of Wnt-5a in cancer , 2009, British Journal of Cancer.

[35]  I. Bisson,et al.  WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics , 2009, Cell Research.

[36]  Raghu Kalluri,et al.  The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[37]  Jie J. Zheng,et al.  Discovery and Characterization of a Small Molecule Inhibitor of the PDZ Domain of Dishevelled* , 2009, The Journal of Biological Chemistry.

[38]  Wenyan Lu,et al.  Suppression of Wnt/beta-catenin signaling inhibits prostate cancer cell proliferation. , 2009, European journal of pharmacology.

[39]  K. Gravdal,et al.  A Switch from E-Cadherin to N-Cadherin Expression Indicates Epithelial to Mesenchymal Transition and Is of Strong and Independent Importance for the Progress of Prostate Cancer , 2007, Clinical Cancer Research.

[40]  Adam S. Kibel,et al.  Integrative molecular concept modeling of prostate cancer progression , 2007 .

[41]  Zijie Sun,et al.  Roles and regulation of Wnt signaling and β-catenin in prostate cancer , 2006 .

[42]  R. Franklin,et al.  The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots , 2006, Molecular Cancer.

[43]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[44]  R. Nusse,et al.  Wnt3a Growth Factor Induces Androgen Receptor-Mediated Transcription and Enhances Cell Growth in Human Prostate Cancer Cells , 2004, Cancer Research.

[45]  A. Potti,et al.  Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. , 2004, Cancer.

[46]  Hosoon Choi,et al.  Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3–independent β-catenin degradation , 2003, The Journal of cell biology.

[47]  Arend Heerschap,et al.  Proton MR spectroscopy of prostatic tissue focused on the etection of spermine, a possible biomarker of malignant behavior in prostate cancer , 2000, Magnetic Resonance Materials in Physics, Biology and Medicine.

[48]  K. Kinzler,et al.  Constitutive Transcriptional Activation by a β-Catenin-Tcf Complex in APC−/− Colon Carcinoma , 1997, Science.

[49]  S. Provencher.  Estimation of metabolite concentrations from localized in vivo proton NMR spectra , 1993, Magnetic resonance in medicine.

[50]  M. Parola,et al.  Polyamines modulate epithelial-to-mesenchymal transition. , 2012, Amino acids.

[51]  K. Koeneman.  Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms , 2009 .

[52]  Zijie Sun,et al.  Roles and regulation of Wnt signaling and beta-catenin in prostate cancer. , 2006, Cancer letters.

[53]  S. Brewster,et al.  Wnt signalling and prostate cancer , 2005, Prostate Cancer and Prostatic Diseases.